Rapid Micro Biosystems (NASDAQ:RPID) & AxoGen (NASDAQ:AXGN) Head to Head Contrast

Rapid Micro Biosystems (NASDAQ:RPID) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Rapid Micro Biosystems and AxoGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-140.30%	-95.40%	-58.85%
AxoGen	-13.21%	-9.63%	-6.26%

Valuation and Earnings

This table compares Rapid Micro Biosystems and AxoGen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59 million	3.42	-$47.12 million	($1.07)	-2.36
AxoGen	$225.21 million	10.22	-$15.70 million	($0.64)	-67.63

AxoGen has higher revenue and earnings than Rapid Micro Biosystems. AxoGen is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 12.7% of Rapid Micro Biosystems shares are held by insiders. Comparatively, 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Rapid Micro Biosystems has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Rapid Micro Biosystems and AxoGen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	1	0	2.00
AxoGen	2	0	9	0	2.64

Rapid Micro Biosystems currently has a consensus target price of $8.00, indicating a potential upside of 216.21%. AxoGen has a consensus target price of $46.50, indicating a potential upside of 7.44%. Given Rapid Micro Biosystems’ higher probable upside, equities research analysts clearly believe Rapid Micro Biosystems is more favorable than AxoGen.

Summary

AxoGen beats Rapid Micro Biosystems on 10 of the 14 factors compared between the two stocks.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.